tbuckley/cabot-search huggingface dataset:
Dental pulp stem cells express tendon markers under mechanical loading and are a potential cell source for tissue engineering of tendon-like tissue
Authors: Yu-Ying Chen, Sheng-Teng He, Fu-Hua Yan, Peng-Fei Zhou, Kai Luo, Yan-Ding Zhang, Yin Xiao, Min-Kui Lin
Journal: International Journal of Oral Science (2016)

Postnatal mesenchymal stem cells have the capacity to differentiate into multiple cell lineages. This study explored the possibility of dental pulp stem cells (DPSCs) for potential application in tendon tissue engineering. The expression of tendon-related markers such as scleraxis, tenascin-C, tenomodulin, eye absent homologue 2, collagens I and VI was detected in dental pulp tissue. Interestingly, under mechanical stimulation, these tendon-related markers were significantly enhanced when DPSCs were seeded in aligned polyglycolic acid (PGA) fibre scaffolds. Furthermore, mature tendon-like tissue was formed after transplantation of DPSC-PGA constructs under mechanical loading conditions in a mouse model. This study demonstrates that DPSCs could be a potential stem cell source for tissue engineering of tendon-like tissue. Research shows that stem cells isolated from adult teeth can develop into tendon tissue and could be used for tendon repair. Tendon injuries are difficult to treat and require long healing periods and/or surgery. Adult stem cells have the potential to improve tissue repair, and they assessed whether stem cells from the teeth could be used. They isolated dental pulp stem cells (DPSCs) from the permanent teeth and showed that they express some tendon-related proteins. When they grew DPSCs on polyglycolic acid scaffolds under mechanical stress on nude mice back, the cells formed tendon tissue that expressed all the crucial tendon-related proteins. The findings show that DPSCs have potential for engineering of tendon-like tissues.
Mirnas and Gene Expression Profiles in CD34+ Cells Are Dependent On the Source of Progenitor Cells Employed in Transplantation.
Authors: Alicia Báez, Beatriz Martin-Antonio, Concepción Prats-Martín, Isabel Álvarez-Laderas, María Victoria Barbado, Teresa Caballero-Velázquez, Jose Ignacio Piruat, Magdalena Carmona, Jose Antonio Pérez-Simón, Alvaro Urbano-Ispizua
Journal: Blood (2012)
Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.
Authors: Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg
Journal: Blood (2005)
Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer.
Authors: Andrea Cercek, Jinru Shia, Marc Gollub, Pamela Joan Raasch, Ellen Hollywood, Diane Lauren Reidy, Yelena Yuriy Janjigian, Zsofia Kinga Stadler, Neil Howard Segal, Eileen Mary O'Reilly, David Ilson, Nancy E. Kemeny, Leonard Saltz
Journal: Journal of Clinical Oncology (2012)

467 Background: To evaluate the safety and efficacy of ganetespib, a heat shock protein 90 (Hsp90) inhibitor, as monotherapy in patients with refractory metastatic colorectal cancer. Methods: A phase II study utilizing a two-stage design was performed in which patients received Ganetespib 200 mg/m2 intravenously (IV) one time per week for three weeks followed by a one week break. Patients underwent pre and 48 hour post treatment tumor biopsies. Immunohistochemistry (IHC) was performed for p/Erk, CyclinD1, p/Akt, HIF-1a, VEGFr2 , p70S6 and Hsp70. Archived and pre dose biopsy tissue was utilized for KRAS, BRAF and PIK3CA genotyping using a Sequenom platform. Results: Fifteen patients were treated (median age 58, range 44-79). There were no responders. Two patients had stable disease lasting 31 and 23 weeks. The most frequent grade 1/2 toxicities were diarrhea, fatigue, nausea/vomiting and elevated transaminases ( Table ). These complications did not result in any treatment interruption. The most frequent grade 3 adverse events were diarrhea (12%), fatigue (24%), and elevated AST(12%) and Alk phos(29%). Three (20%) patients required dose reductions, 1 grade 3 AST, 1 grade3 ALT and 1 grade 3 fatigue. Conclusions: This was the first study of an Hsp90 inhibitor in colorectal cancer. Ganetespib treatment did not produce tumor responses when administered as a single agent in refractory metastatic colorectal cancer with this dosing regimen. Overall the drug was well tolerated and the toxicity profile was minimal. Ganetespib may be used in combination in future studies. Correlative IHC analyses will be presented. [Table: see text]
Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma
Authors: Pallawi Torka, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Bruno Paiva, Christine M. Ho, Maureen Ross, Francisco J. Hernandez-Ilizaliturri, Philip L. McCarthy, Theresa Hahn
Journal: Blood (2015)
Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study
Authors: Andres Forero-Torres, Beata Holkova, Jeff P. Sharman, Jonathan W. Friedberg, Maurice J. Berkowitz, William Fintel, Robert Chen, Ralph V. Boccia, Mansoor Saleh, Neil Josephson, Maria Corinna Palanca-Wessels, Christopher A. Yasenchak
Journal: Blood (2014)
Adoptive Treatment Of EBV-Associated Leiomyosarcoma In Immunodeficient Patients With EBV Specific Cytotoxic T Cells
Authors: Susan E. Prockop, Ekaterina Doubrovina, Farid Boulad, Nancy A. Kernan, Rachel Kobos, Andromachi Scaradavou, Sara J. Abramson, Michael Laquaglia, Anita Price, Richard J. O’Reilly
Journal: Blood (2013)
Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology (supportive care) Trial to Evaluate Comparative Treatment Results
Authors: Kimberley Blackwell, Ruslan Paltuev, Roman Donskih, Olga Burdaeva, Elena Bit-Sava, Tanveer Maksud, Michael Jones, Allen Nixon, Maria J Vidal, Roumen Nakov, Pritba Singh, Gregor Schaffer, Pere Gascon, Nadia Harbeck
Journal: Blood (2015)
INVESTIGATION OF THE REWARD VALUE OF EXERCISE IN COMPARISON WITH FOOD AND MONEY
Authors: A. Albelwi, R Rogers, HP Kubis
Journal: British Journal of Sports Medicine (2016)

The aim of the present study was to determine the effect of 4 weeks high intensity intermittent Taekwondo (TKD) training program on body composition, physical fitness and performance of South African TKD athletes of Zulu ancestry. Thirty four (n=34) active TKD athletes aged 20–26 y volunteered for this study. The athletes were divided into control and experimental groups. The control participants (10 males and 7 females) are holders of green or lower belts with provincial championship exposure. The experimental group (10 males and 7 females) had blue or senior belts that had provincial and international championships exposure. Both groups were subjected to 4 weeks of TKD and strength training. The experimental group was made to perform high intensity intermittent (85–95 % VO 2max ) training, while the control group performed interval TKD training of lower intensity (70–75 % VO 2max ). All experimental participants were pre- and post-tested parameters of body composition [body mass, body fat percentage (% BF), sum of 6 skinfolds (SS)], flexibility (sit &amp; reach), leg power (standing broad jump), muscle strength and endurance (sit-ups and push-ups), agility (T-test), VO 2max (20 m bleep test). Resting heart rate (RHR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Data was analyzed using paired t -test for independent samples and Z-score individual radar plots statistics for assessment of each athlete. After 4 weeks of training, athletes in the experimental group showed a reduction in body weight (p&lt;0.05), BMI (p&lt;0.001), SBP (p&lt;0.05), RHR (p&lt;0.05), SS (p&lt;0.05), and fat % (p&lt;0.001) and improvement (p&lt;0.001) in flexibility, muscle strength, power, agility and VO 2max . In male controls, fat % was decreased (p&lt;0.05), flexibility and VO 2max were increased (p&lt;0.05). In female controls, only flexibility was improved (p&lt;0.05). The findings of this study support the effectiveness of 4 weeks high intensity intermittent training in Taekwondo athletes of Zulu ancestry improves body composition, cardiorespiratory response and physical performance that could contribute to enhanced combat skills.
Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Werner Rabitsch, Alexandra Boehm, Peter Schellongowski, Peter Kalhs, Peter Valent, Wolfgang R Sperr
Journal: Blood (2012)
Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)
Authors: Marie Y. Detrait, Patrice Chevallier, Mohamad Sobh, Thierry Guillaume, Xavier Thomas, Stephane Morisset, Nathalie Tedone, Jacques Delaunay, Franck E. Nicolini, Helene Labussiere, Sophie Ducastelle, Jihane Fattoum, Fiorenza Barraco, Giovanna Cannas, Youcef Chelghoum, Mohamad Mohty, Mauricette Michallet
Journal: Blood (2011)
As Opioid Epidemic Rages, Complementary Health Approaches to Pain Gain Traction
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge
Authors: Vicki Stone, Mark R. Miller, Martin J.D. Clift, Alison Elder, Nicholas L. Mills, Peter Møller, Roel P.F. Schins, Ulla Vogel, Wolfgang G. Kreyling, Keld Alstrup Jensen, Thomas A.J. Kuhlbusch, Per E. Schwarze, Peter Hoet, Antonio Pietroiusti, Andrea De Vizcaya-Ruiz, Armelle Baeza-Squiban, João Paulo Teixeira, C. Lang Tran, Flemming R. Cassee
Journal: Environmental Health Perspectives (2016)

Background: A rich body of literature exists that has demonstrated adverse human health effects following exposure to ambient air particulate matter (PM), and there is strong support for an important role of ultrafine (nanosized) particles. At present, relatively few human health or epidemiology data exist for engineered nanomaterials (NMs) despite clear parallels in their physicochemical properties and biological actions in in vitro models. Objectives: NMs are available with a range of physicochemical characteristics, which allows a more systematic toxicological analysis. Therefore, the study of ultrafine particles (UFP, <100 nm in diameter) provides an opportunity to identify plausible health effects for NMs, and the study of NMs provides an opportunity to facilitate the understanding of the mechanism of toxicity of UFP. Methods: A workshop of experts systematically analyzed the available information and identified 19 key lessons that can facilitate knowledge exchange between these discipline areas. Discussion: Key lessons range from the availability of specific techniques and standard protocols for physicochemical characterization and toxicology assessment to understanding and defining dose and the molecular mechanisms of toxicity. This review identifies a number of key areas in which additional research prioritization would facilitate both research fields simultaneously. Conclusion: There is now an opportunity to apply knowledge from NM toxicology and use it to better inform PM health risk research and vice versa. https://doi.org/10.1289/EHP424
Studies of Peonies
Authors: M. Therese Southgate
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML)
Authors: Ahmed Aribi, Cedric Dos Santos, Margaret O' Donnell, Anthony S. Stein, Allen Lin, Joycelynne M. Palmer, Meng Zhuo, David Snyder, Haris Ali, Robert Chen, Leslie L. Popplewell, Nitya Nathwani, Samer K Khaled, Amandeep Salhotra, Alex Herrera, Ibrahim Aldoss, Eileen P. Smith, Guido Marcucci, Stephen J. Forman, Ravi Bhatia
Journal: Blood (2015)
Magnetically Controlled Drug Release System through Magnetomechanical Actuation
Authors: João Barbosa, Daniela Maria Correia, Renato Gonçalves, Clarisse Ribeiro, Gabriela Botelho, Pedro Martins, Senentxu Lanceros‐Mendez
Journal: Advanced Healthcare Materials (2016)

A drug release system is developed capable to modulate the drug release kinetics by the application of a magnetic field. Thus, this work reports on the production, characterization, and release kinetics of a poly( l ‐lactic acid) (PLLA) microporous membrane containing a zeolite (Faujasite) and a magnetic stimuli‐sensitive component, magnetostrictive Terfenol‐D (TD), for the release of ibuprofen (IBU) as drug model. For membranes containing IBU‐loaded zeolites and TD without an applied AC magnetic field, the release kinetics is characterized by a first order release. On the other hand, the application of an AC magnetic field modifies the release profile of the membrane, leading to an increase of the release rate by more than 30%, the magnetically driven release being characterized by a super case‐II within the Korsmeyer–Peppas model, indicating a release mainly driven by a swelling or erosion mechanism, induced by the magnetostrictive particles under the applied magnetic field. The increase of the TD w/w from 10% to 20% has as a consequence a decrease in the quantity of IBU released from 79% to 70%; on the contrary, increasing the H AC intensity from 100 to 200 mT promotes an increase on the percentage of IBU released from 67% to 75%.
Uncommon Syndromes and Treatment Manifestations of Malignancy
Authors: Kannan Ramar, Anil Potti, Syed A. Mehdi
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.01.052 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12506189 Uncommon Syndromes and Treatment Manifestations of Malignancy Case 4. Periorbital Edema and Imatinib Mesylate Therapy for Chronic Myelogenous Leukemia Kannan RamarxKannan RamarSearch for articles by this author , Anil PottixAnil PottiSearch for articles by this author , Syed A. MehdixSyed A. MehdiSearch for articles by this author Show More Department of Medicine and Division of Oncology, University of North Dakota School of Medicine; and the Division of Oncology, VA Medical Center, Fargo, ND https://doi.org/10.1200/JCO.2003.01.052 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.
Authors: Fanqi Bai, J.-X. Zou, Sheng Wei, Jeffrey S. Painter, Michelle Blaskovich, Said Sebti, Thomas P. Loughran, P.K. Epling-Burnette
Journal: Blood (2007)
Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).
Authors: Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Deborah A. Thomas, Stefan Faderl, Dan Jones, Elias Jabbour, Charles Koller, Samuel Dara, Rebecca Garris, Partow Kebriaei, Gautam Borthakur, Alessandra Ferrajoli, Susan O'Brien
Journal: Blood (2009)
Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.
Authors: Hiroshi Yasui, Teru Hideshima, Aldo M. Roccaro, Norihiko Shiraishi, Makoto Hamasaki, Kenji Ishitsuka, Shaji Kumar, Noopur Raje, Guilan Li, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2004)
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults
Authors: Don L. Longo, Patricia L. Duffey, Elaine S. Jaffe, Mark Raffeld, Susan M. Hubbard, Richard I. Fisher, Robert E. Wittes, Vincent T. DeVita, Robert C. Young
Journal: Journal of Clinical Oncology (1996)

A 1994 report by Longo et al, entitled "Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults: A High-Grade Lymphoma Responsive to ProMACE-Based Combination Chemotherapy" (J Clin Oncol 12:2153–2159) contained an error. In the Patients and Methods section, on page 2155, line 6 of the left column should have read: ". ...bleomycin 5U/m day 8, methotrexate 120 mg/m 2 on day 8... ."
The Mechanisms of Mobilization of Hematopoietic Stem Cell and Progenitor Cell by HGF.
Authors: Fumihito Tajima, Hiroyuki Tsuchiya, Tetsuya Tanimoto, Akihito Yonezawa, Shohei Yamaoka, Tack-Joong Kim, Kenichi Nishikawa, Toshiro Okazaki, Goshi Shiota
Journal: Blood (2005)
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens
Authors: Rohtesh S. Mehta, Rima M Saliba, Kai Cao, Indreshpal Kaur, Katayoun Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marin, Amin M. Alousi, Chitra Hosing, Uday R. Popat, Partow Kebriaei, Richard E. Champlin, Ian K. McNiece, Marcos De Lima, Donna Skerrett, Elizabeth Burke, Elizabeth J. Shpall, Betul Oran
Journal: Blood (2015)
Tobacco Cessation Treatment Pathways for Patients With Cancer: 10 Years in the Making
Authors: Maher Karam-Hage, Hanadi Ajam Oughli, Vance Rabius, Diane Beneventi, Rosario C. Wippold, Janice A. Blalock, Paul M. Cinciripini
Journal: Journal of the National Comprehensive Cancer Network (2016)

Tobacco use is the most common cause of preventable morbidity and mortality in the United States; it accounts for one-third of all cancer deaths and is thought to account for half of preventable cancer deaths. This article describes the Tobacco Treatment Program at a major academic cancer center. Patients and employees may access these services in a number of ways. All current smokers and recent quitters are proactively contacted and invited to participate. Services provided are tailored to the motivational level of individual patients and their immediate medical needs. The treatment pathways we present are based on our experience from the last 10 years in treating more than 5,000 unique patients with around 60,000 patient visits. These pathways include behavioral counseling and pharmacotherapy, including first-line, second-line, and off-label medication use. This article describes the program with the goal of providing guidance and ideas to others who are developing treatment programs and providing treatment to tobacco users.
First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma
Authors: Y. Beldjilali, K. A. Benhadji, A. Boukerche, H. Khellafi, A. Abdelaoui, F. Betkaoui, Z. K. Tourabi, M. Y. Kaïd, L. Djellali, M. Yamouni
Journal: Journal of Clinical Oncology (2009)

6045 Background: The purpose of this phase II study is to assess a new induction chemotherapy regimen combining cisplatin (P), docetaxel (T), and capecitabine (X) in advanced nasopharyngeal carcinoma. Methods: Previously untreated patients (pts) with histological diagnosed locally advanced nasopharyngeal carcinoma (stages III, IVA, and IVB UICC 2002) received induction chemotherapy associating P 75 mg/m 2 , T 75 mg/m 2 , both on day 1 and X 1,000 mg/m 2 /d days 1–14. Cycles were repeated every 3 weeks. A total of 4 cycles was planned for each patient. Induction chemotherapy was followed by concurrent chemo-radiotherapy: P 75 mg/m 2 days 1, 22, 42 and radiotherapy (65–70 Gy) 4 to 6 weeks after the fourth cycle of induction treatment. Primary end point was tumor response of the induction regimen. Pts were evaluated according to RECIST criteria by clinical examination and CT scan of the nasopharynx. Results: 40 pts (26 male and 14 female) were enrolled. Median age was 40 years (range 18–56), ECOG performance status was 0–1 in all pts. 30 pts (75%) had an undifferentiated carcinoma of nasopharyngeal type (UCNT) and 10 pts (25%) a poorly differentiated nasopharyngeal carcinoma. 5 pts had stage III disease, 20 pts stage IVA disease and 15 pts stage IVB. Toxicity and tumor response were assessable in 40 pts. After 160 cycles, grade 3–4 toxicities (NCI-CTC 3.0) were: neutropenia (11 %), anemia (10.5%), nausea and vomiting (28%), diarrhea (8%), mucositis (3%), reversible alopecia (100%), and fatigue (10%). No febrile neutropenia was noted. 2 pts had grade 3 renal toxicity and only one patient had hand-foot syndrome (grade 3). Response rates for the 40 pts were: complete response 48%, partial response 40%, stable disease 4%, and progressive disease 8%. Conclusions: PTX induction chemotherapy resulted on a high response rate with manageable toxicity. Outcome of patients after chemoradiotherapy is awaited to evaluate the effectiveness of this new treatment modality. No significant financial relationships to disclose.
Modeling the Genotoxicity of Viral Vector Integration in a Tumor Prone Hematopoietic Stem Cell Transplantation Model.
Authors: Eugenio Montini, Daniela Cesana, Manfred Schmidt, Francesca Sanvito, Maurilio Ponzoni, Lucia Sergi Sergi, Fabrizio Benedicenti, Cynthia Bartholomae, Clelia Di Serio, Claudio Doglioni, Christof von Kalle, Luigi Naldini
Journal: Blood (2006)
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol
Authors: Franco Locatelli, Maura Faraci, Simone Cesaro, Daria Pagliara, Franca Fagioli, Marco Zecca, Vian Amber, Kamalika Banerjee, Giorgia Finetto, Fabio Ciceri
Journal: Blood (2015)